SIMPONI (Golimumab) 50mg/0.5mL solution for SC inj from Centocor Ortho Biotech The FDA has approved Simponi (golimumab for subcutaneous injection; Janssen Biotech) to induce and maintain clinical ...

AVT03, Alvotech’s proposed biosimilar to Prolia ® and Xgeva ® (denosumab), is partnered with Dr. Reddy’s Laboratories Ltd. which, as applicant, is responsible for the U.S. regulatory submission.

Two interchangeable golimumab biosimilars were approved for the treatment of rheumatoid arthritis and ulcerative colitis.

SAN DIEGO — Findings from a new study indicate that more than half of the patients with ulcerative colitis who received subcutaneous injections of a drug used to treat autoimmune disorders responded ...

The U.S. Food and Drug Administration has approved the first interchangeable biosimilars of Simponi and Simponi Aria (golimumab) for the treatment of rheumatoid arthritis and ulcerative ...

If you have a certain kind of autoimmune condition, your doctor might suggest Simponi or Simponi Aria as a treatment option for you. The active ingredient in Simponi and Simponi Aria is golimumab. An ...

The CHMP positive opinion was based on the findings from the GO-AHEAD study, which demonstrated significant clinical improvement in patients with active nr-axial SpA treated with golimumab, compared ...

Subcutaneous (subQ or SQ) injections are shots given in the fatty tissue layer (subcutaneous fat) under your skin. Your skin has many layers, and the subcutaneous layer is beneath the epidermis and ...

Simponi and Simponi Aria (golimumab) can cause mild to serious side effects. A more common side effect includes upper respiratory infection. If side effects from the drug become difficult to tolerate, ...